ExodusPoint Capital Management’s AbCellera Biologics ABCL Stock Holding History

ExodusPoint Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$498K	Buy	142,746 +29,678	+26%	+$107K	﹤0.01%	1191
2025 Q4	$387K	Buy	+113,068	New	+$505K	﹤0.01%	1246
2025 Q1	–	Sell	-281,795	Closed	-$826K	–	1396
2024 Q4	$826K	Buy	+281,795	New	+$785K	0.01%	1003
2024 Q2	–	Sell	-496,012	Closed	-$2.25M	–	1461
2024 Q1	$2.25M	Buy	496,012 +362,358	+271%	+$1.85M	0.02%	652
2023 Q4	$763K	Buy	+133,654	New	+$619K	0.01%	910
2023 Q3	–	Sell	-214,557	Closed	-$1.39M	–	1633
2023 Q2	$1.39M	Sell	214,557 -37,635	-15%	-$257K	0.01%	972
2023 Q1	$1.9M	Buy	252,192 +71,842	+40%	+$652K	0.02%	901
2022 Q4	$1.83M	Buy	180,350 +5,600	+3%	+$64.7K	0.03%	684
2022 Q3	$1.73M	Sell	174,750 -87,753	-33%	-$963K	0.02%	864
2022 Q2	$2.8M	Buy	262,503 +133,652	+104%	+$1.13M	0.03%	644
2022 Q1	$1.26M	Buy	128,851 +46,026	+56%	+$436K	0.02%	1016
2021 Q4	$1.18M	Buy	+82,825	New	+$1.26M	0.01%	983
2021 Q3	–	Sell	-29,972	Closed	-$659K	–	2031
2021 Q2	$659K	Buy	29,972 +20,729	+224%	+$572K	0.01%	1216
2021 Q1	$314K	Sell	9,243 -19,607	-68%	-$781K	﹤0.01%	1635
2020 Q4	$1.16M	Buy	+28,850	New	+$1.32M	0.01%	776

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ExodusPoint Capital Management's ABCL Position: Q1 2026 in Review

ExodusPoint Capital Management increased its AbCellera Biologics (ABCL) stake by 26% in Q1 2026, buying an estimated $107K and bringing the position to 142,746 shares worth $498K. The position accounts for ﹤0.01% of the portfolio, ranked #1191.

ExodusPoint Capital Management first reported a position in ABCL in Q4 2020 and has held it in 15 quarters since. The position peaked at $2.8M in Q2 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

ExodusPoint Capital Management held 142,746 shares of AbCellera Biologics worth $498K as of Q1 2026.
ExodusPoint Capital Management bought 29,678 AbCellera Biologics shares in Q1 2026, an estimated $107K.
AbCellera Biologics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1191 holding.
ExodusPoint Capital Management first reported a position in AbCellera Biologics in Q4 2020 and has held it in 15 quarters since.
ExodusPoint Capital Management's AbCellera Biologics position peaked at $2.8M in Q2 2022.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.